1. Neuroendocrine Breast Cancer. Clinical Observation. Personalized Approach
- Author
-
Sh. Kh. Gantsev, G. Schaller, K. Sh. Gantsev, A. N. Plikhta, Sh. R. Kzyrgalin, and R. A. Rustamkhanov
- Subjects
0301 basic medicine ,mammary gland ,medicine.medical_specialty ,RD1-811 ,medicine.medical_treatment ,synaptophysin ,Neuroendocrine tumors ,precision drug therapy ,03 medical and health sciences ,breast cancer ,0302 clinical medicine ,Breast cancer ,Breast Fibroadenoma ,medicine ,Stage (cooking) ,radiotherapy ,RC254-282 ,medicine.diagnostic_test ,business.industry ,chromogranin a ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Cancer ,General Medicine ,medicine.disease ,Radiation therapy ,Regimen ,030104 developmental biology ,Positron emission tomography ,030220 oncology & carcinogenesis ,Surgery ,Radiology ,neuroendocrine tumors ,business - Abstract
Introduction. Neuroendocrine breast tumors represent a rare subtype of breast cancer, accounting for less than 1 % of all neuroendocrine neoplasms. Starting from their pathology definition, and going through their prevalence, prognosis and treatment, our knowledge is still really uncertain.Materials and methods. The article presents a rare clinical observation of a neuroendocrine breast tumor. A breast fibroadenoma was diagnosed at the initial diagnosis stage in a private clinic; after a surgical treatment and further morphological study, it was estimated: a diagnosis of Cancer in situ of the left breast T1N0M0, stage I. Next, 3D-conformal remote radiation therapy was performed on the area of the left breast.Results and discussion. After conducting positron emission tomography, multiple metastases were detected in the lymph nodes, bones, and liver. Additionally, micropreparations were consulted at the Federal Reference Center in St. Petersburg and at an independent third-party molecular biological laboratory in Germany (Munich). Given all the instrumental, molecular biological, histological and immunohistochemical studies of the patient, an individual regimen of drug therapy was selected.Conclusion. After 18 months of personalized drug therapy, we observed a positive trend and a significant decrease in metabolic activity according to positron emission tomography.
- Published
- 2021
- Full Text
- View/download PDF